[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Gastric cancer,Cadonilimab,PD-1\/CTLA-4 bispecific antibody,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. Ji<\/b><sup>1<\/sup>, L. Shen<sup>1<\/sup>, Z. Li<sup>1<\/sup>, X. Zhang<sup>1<\/sup>, X. Gao<sup>1<\/sup>, Y. Zhang<sup>2<\/sup>, B. Liu<sup>3<\/sup>, Y. Wang<sup>4<\/sup>, N. Li<sup>5<\/sup>, Y. Ba<sup>6<\/sup>, R. Zhang<sup>7<\/sup>, J. Zhang<sup>8<\/sup>, Y. Chen<sup>9<\/sup>, J. Chen<sup>10<\/sup>, Y. Fu<sup>11<\/sup>, M. Huang<sup>12<\/sup>, M. Liu<sup>13<\/sup>, Z. Liu<sup>14<\/sup>, J. Zhao<sup>15<\/sup>, W. Li<sup>16<\/sup>, C. Li<sup>3<\/sup>, J. Wei<sup>17<\/sup>, N. Xu<sup>18<\/sup>, B. Cao<sup>19<\/sup>, Z. Guo<sup>20<\/sup>, L. Liu<sup>21<\/sup>, P. Nie<sup>22<\/sup>, L. Sheng<sup>23<\/sup>, L. Wan<sup>24<\/sup>, K. Gu<sup>25<\/sup>, Z. Liu<sup>26<\/sup>, W. Wang<sup>27<\/sup>, Y. He<sup>28<\/sup>, G. Wu<sup>29<\/sup>, F. Zhang<sup>30<\/sup>, J. Guo<sup>31<\/sup>, W. Qiu<sup>32<\/sup>, J. Ying<sup>33<\/sup>, H. Pan<sup>34<\/sup>, Y. Bai<sup>35<\/sup>, H. Xu<sup>36<\/sup>, Z. Wang<sup>37<\/sup>, Y. Yuan<sup>38<\/sup>, X. Zhao<sup>39<\/sup>, J. Xu<sup>40<\/sup>, Z. Yao<sup>41<\/sup>, W. Liu<sup>41<\/sup>, Z. M. Wang<sup>41<\/sup>, B. Li<sup>41<\/sup>, M. Xia<sup>41<\/sup>; <br\/><sup>1<\/sup>Beijing Cancer Hospital, Beijing, China, <sup>2<\/sup>Affiliated Tumor Hospital of Harbin Medical University, Harbin, China, <sup>3<\/sup>Shandong Cancer Hospital, Jinan, China, <sup>4<\/sup>Shanxi Cancer Hospital, Taiyuan, China, <sup>5<\/sup>Henan Cancer Hospital, Zhengzhou, China, <sup>6<\/sup>Tianjin Medical University Cancer Institute & Hospital, Tianjin, China, <sup>7<\/sup>Fourth Hospital of Hebei Medical University, Shijiazhuang, China, <sup>8<\/sup>Liaoning Provincial Cancer Hospital, Shenyang, China, <sup>9<\/sup>The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China, <sup>10<\/sup>Yantai Yuhuangding Hospital, Yantai, China, <sup>11<\/sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, <sup>12<\/sup>Fudan University Cancer Hospital, Shanghai, China, <sup>13<\/sup>The First Affiliated Hospital of Bengbu Medical College, Bengbu, China, <sup>14<\/sup>Handan Central Hospital, Handan, China, <sup>15<\/sup>Changzhi People's Hospital, Changzhi, China, <sup>16<\/sup>The First Hospital of Jilin University, Changchun, China, <sup>17<\/sup>Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, China, <sup>18<\/sup>The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, <sup>19<\/sup>Beijing Friendship Hospital, Capital Medical University, Beijing, China, <sup>20<\/sup>Fujian Provincial Cancer Hospital, Fuzhou, China, <sup>21<\/sup>Qilu Hospital of Shandong University, Jinan, China, <sup>22<\/sup>Wuwei Cancer Hospital, Wuwei, China, <sup>23<\/sup>Yijishan Hospital of Wannan Medical College, Wuhu, China, <sup>24<\/sup>Nanyang Central Hospital, Nanyang, China, <sup>25<\/sup>The First Affiliated Hospital of Anhui Medical University, Hefei, China, <sup>26<\/sup>Hunan Cancer Hospital, Changsha, China, <sup>27<\/sup>Shandong Provincial Hospital, Jinan, China, <sup>28<\/sup>Anhui Provincial Cancer Hospital, Hefei, China, <sup>29<\/sup>Meizhou People's Hospital, Meizhou, China, <sup>30<\/sup>Shijiazhuang People's Hospital, Shijiazhuang, China, <sup>31<\/sup>Xingtai People's Hospital, Xingtai, China, <sup>32<\/sup>Affiliated Hospital of Qingdao University, Qingdao, China, <sup>33<\/sup>Zhejiang Cancer Hospital, Hangzhou, China, <sup>34<\/sup>Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, China, <sup>35<\/sup>China-Japan Union Hospital of Jilin University, Changchun, China, <sup>36<\/sup>Hubei Cancer Hospital, Wuhan, China, <sup>37<\/sup>The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, China, <sup>38<\/sup>Xuzhou Central Hospital, Xuzhou, China, <sup>39<\/sup>Linfen Central Hospital, Linfen, China, <sup>40<\/sup>Zhoukou Central Hospital, Zhoukou, China, <sup>41<\/sup>Akeso Biopharma, Inc., Zhongshan, China","CSlideId":"","ControlKey":"575482db-ad0f-4cc6-8006-40e5e5c00f7c","ControlNumber":"9590","DisclosureBlock":"&nbsp;<b>J. Ji, <\/b> None..<br><b>L. Shen, <\/b> None..<br><b>Z. Li, <\/b> None..<br><b>X. Zhang, <\/b> None..<br><b>X. Gao, <\/b> None..<br><b>Y. Zhang, <\/b> None..<br><b>B. Liu, <\/b> None..<br><b>Y. Wang, <\/b> None..<br><b>N. Li, <\/b> None..<br><b>Y. Ba, <\/b> None..<br><b>R. Zhang, <\/b> None..<br><b>J. Zhang, <\/b> None..<br><b>Y. Chen, <\/b> None..<br><b>J. Chen, <\/b> None..<br><b>Y. Fu, <\/b> None..<br><b>M. Huang, <\/b> None..<br><b>M. Liu, <\/b> None..<br><b>Z. Liu, <\/b> None..<br><b>J. Zhao, <\/b> None..<br><b>W. Li, <\/b> None..<br><b>C. Li, <\/b> None..<br><b>J. Wei, <\/b> None..<br><b>N. Xu, <\/b> None..<br><b>B. Cao, <\/b> None..<br><b>Z. Guo, <\/b> None..<br><b>L. Liu, <\/b> None..<br><b>P. Nie, <\/b> None..<br><b>L. Sheng, <\/b> None..<br><b>L. Wan, <\/b> None..<br><b>K. Gu, <\/b> None..<br><b>Z. Liu, <\/b> None..<br><b>W. Wang, <\/b> None..<br><b>Y. He, <\/b> None..<br><b>G. Wu, <\/b> None..<br><b>F. Zhang, <\/b> None..<br><b>J. Guo, <\/b> None..<br><b>W. Qiu, <\/b> None..<br><b>J. Ying, <\/b> None..<br><b>H. Pan, <\/b> None..<br><b>Y. Bai, <\/b> None..<br><b>H. Xu, <\/b> None..<br><b>Z. Wang, <\/b> None..<br><b>Y. Yuan, <\/b> None..<br><b>X. Zhao, <\/b> None..<br><b>J. Xu, <\/b> None.&nbsp;<br><b>Z. Yao, <\/b> <br><b>Akeso Biopharma, Inc.<\/b> Employment. <br><b>W. Liu, <\/b> <br><b>Akeso Biopharma, Inc.<\/b> Employment. <br><b>Z. M. Wang, <\/b> <br><b>Akeso Biopharma, Inc.<\/b> Employment. <br><b>B. Li, <\/b> <br><b>Akeso Biopharma, Inc.<\/b> Employment. <br><b>M. Xia, <\/b> <br><b>Akeso Biopharma, Inc.<\/b> Employment.","End":"4\/7\/2024 3:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"11423","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT006","PresenterBiography":null,"PresenterDisplayName":"Jiafu Ji, MD;PhD","PresenterKey":"32b83355-33a6-490b-8d08-497cb1580415","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT006. Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma (COMPASSION-15): A randomized, double-blind, phase 3 trial","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:30PM","SessionId":"660","SessionOnDemand":"False","SessionTitle":"Novel Immune Checkpoint Inhibitor Combinations","ShowChatLink":"false","Start":"4\/7\/2024 3:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Cadonilimab plus chemotherapy versus chemotherapy as first-line treatment for unresectable locally advanced or metastatic gastric or gastroesophageal junction (G\/GEJ) adenocarcinoma (COMPASSION-15): A randomized, double-blind, phase 3 trial","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"c71b87b8-80a4-46ed-8191-62f2f7f70019","ControlNumber":"12132","DisclosureBlock":"","End":"4\/7\/2024 4:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11831","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:30PM","SessionId":"660","SessionOnDemand":"False","SessionTitle":"Novel Immune Checkpoint Inhibitor Combinations","ShowChatLink":"false","Start":"4\/7\/2024 3:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CL08-02 Molecular targeted therapy,,"},{"Key":"Keywords","Value":"PIK3CA,Molecular targets,Colorectal cancer,Combination therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>E. S. Christenson<\/b><sup>1<\/sup>, J. A. Wala<sup>2<\/sup>, R. Parkinson<sup>1<\/sup>, N. B. Collins<sup>2<\/sup>, C. Jakubowski<sup>1<\/sup>, J.-R. Lin<sup>3<\/sup>, H. Wang<sup>1<\/sup>, W. Ho<sup>1<\/sup>, S. Chan<sup>2<\/sup>, R. Klein<sup>1<\/sup>, Y. Cetasaan<sup>1<\/sup>, E. Johnson<sup>2<\/sup>, M. Berg<sup>1<\/sup>, J. Meyerhardt<sup>2<\/sup>, B. Schlechter<sup>2<\/sup>, H. Singh<sup>2<\/sup>, P. K. Sorger<sup>3<\/sup>, M. Giannakis<sup>2<\/sup>, N. Azad<sup>1<\/sup>; <br\/><sup>1<\/sup>The Johns Hopkins Hospital, Baltimore, MD, <sup>2<\/sup>Dana Farber Cancer Institute, Boston, MA, <sup>3<\/sup>Harvard Medical School, Boston, MA","CSlideId":"","ControlKey":"83dce547-f00e-48f3-9607-8a72183be16c","ControlNumber":"10418","DisclosureBlock":"<b>&nbsp;E. S. Christenson, <\/b> <br><b>NextCure<\/b> Grant\/Contract. <br><b>Haystack Oncology<\/b> Grant\/Contract. <br><b>Pfizer Inc.<\/b> Grant\/Contract. <br><b>Affimed GMBH<\/b> Grant\/Contract. <br><b>Seres Therapeutics<\/b> Other, Consulting. <br><b>SIRTeX<\/b> Other, Consulting.<br><b>J. A. Wala, <\/b> None..<br><b>R. Parkinson, <\/b> None..<br><b>N. B. Collins, <\/b> None..<br><b>C. Jakubowski, <\/b> None..<br><b>J. Lin, <\/b> None..<br><b>H. Wang, <\/b> None..<br><b>W. Ho, <\/b> None..<br><b>S. Chan, <\/b> None..<br><b>R. Klein, <\/b> None..<br><b>Y. Cetasaan, <\/b> None..<br><b>E. Johnson, <\/b> None..<br><b>M. Berg, <\/b> None..<br><b>J. Meyerhardt, <\/b> None..<br><b>B. Schlechter, <\/b> None.&nbsp;<br><b>H. Singh, <\/b> <br><b>Astrazeneca<\/b> Grant\/Contract. <br><b>Dewpoint Therapeutics<\/b> Other, Consulting. <br><b>Sharpe & Dohme<\/b> Other, Consulting. <br><b>Merck<\/b> Other, Consulting. <br><b>Dava Oncology<\/b> Travel.<br><b>P. K. Sorger, <\/b> None..<br><b>M. Giannakis, <\/b> None..<br><b>N. Azad, <\/b> None.","End":"4\/7\/2024 4:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11424","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT007","PresenterBiography":null,"PresenterDisplayName":"Eric Christenson, BS;MD","PresenterKey":"512c8955-c94e-4702-aa18-f5f2520b92ab","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT007. Phase 1\/2 trial of copanlisib in combination with nivolumab for microsatellite stable (MSS) colorectal cancer (CRC)","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:30PM","SessionId":"660","SessionOnDemand":"False","SessionTitle":"Novel Immune Checkpoint Inhibitor Combinations","ShowChatLink":"false","Start":"4\/7\/2024 4:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1\/2 trial of copanlisib in combination with nivolumab for microsatellite stable (MSS) colorectal cancer (CRC)","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"21214136-9027-45b0-8d86-001e0eba0d0f","ControlNumber":"12133","DisclosureBlock":"","End":"4\/7\/2024 4:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11832","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:30PM","SessionId":"660","SessionOnDemand":"False","SessionTitle":"Novel Immune Checkpoint Inhibitor Combinations","ShowChatLink":"false","Start":"4\/7\/2024 4:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL05-01 Phase II adult clinical trials,,"},{"Key":"Keywords","Value":"Endometrial cancer,Antibody-drug conjugate (ADC),Immunotherapy,Folate receptor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>R. L. Porter<\/b>, N. Xiong, N. Tayob, M. Polak, H. Sawyer, M. Hayes, J. Gardner, S. Campos, N. Horowitz, C. Krasner, E. K. Lee, J. F. Liu, E. H. Stover, J. Veneris, A. A. Wright, U. A. Matulonis, P. Konstantinopoulos; <br\/>Dana-Farber Cancer Institute, Boston, MA","CSlideId":"","ControlKey":"8d71adf0-4f33-493a-b5b5-254cfd4c6065","ControlNumber":"9821","DisclosureBlock":"<b>&nbsp;R. L. Porter, <\/b> <br><b>GSK<\/b> Other, Scientific Advisory Board.<br><b>N. Xiong, <\/b> None..<br><b>N. Tayob, <\/b> None..<br><b>M. Polak, <\/b> None..<br><b>H. Sawyer, <\/b> None..<br><b>M. Hayes, <\/b> None..<br><b>J. Gardner, <\/b> None.&nbsp;<br><b>S. Campos, <\/b> <br><b>Immunogen<\/b> Other, Advisory Board.<br><b>N. Horowitz, <\/b> None..<br><b>C. Krasner, <\/b> None..<br><b>E. K. Lee, <\/b> None.&nbsp;<br><b>J. F. Liu, <\/b> <br><b>2X Oncology<\/b> Grant\/Contract. <br><b>Aravive<\/b> Grant\/Contract. <br><b>Arch Oncology<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Advisory Board\/consulting. <br><b>BMS<\/b> Grant\/Contract, Other, Advisory Board\/consulting. <br><b>Clovis Oncology<\/b> Grant\/Contract, Other, Advisory Board\/consulting. <br><b>GSK<\/b> Grant\/Contract, Other, Advisory Board\/consulting. <br><b>Impact Therapeutics<\/b> Grant\/Contract. <br><b>Regeneron<\/b> Grant\/Contract, Other, Advisory Board\/consulting. <br><b>Seagen<\/b> Grant\/Contract. <br><b>Vigeo Therapeutics<\/b> Grant\/Contract. <br><b>Zentalis Pharmaceuticals<\/b> Grant\/Contract, Other, Advisory Board\/consulting. <br><b>Daiichi Sankyo<\/b> Other, Advisory Board\/consulting. <br><b>Eisai<\/b> Other, Advisory Board\/consulting. <br><b>Genentech<\/b> Other, Advisory Board\/consulting.<br><b>E. H. Stover, <\/b> None..<br><b>J. Veneris, <\/b> None.&nbsp;<br><b>A. A. Wright, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Consultant. <br><b>GSK<\/b> Grant\/Contract, Other, Consultant. <br><b>Medtronic<\/b> Grant\/Contract. <br><b>Merck<\/b> Other, Consultant. <br><b>U. A. Matulonis, <\/b> <br><b>Nextcure<\/b> Other, Scientific Advisory Board. <br><b>Tango<\/b> Other, Scientific Advisory Board. <br><b>ProFound Bio<\/b> Other, Scientific Advisory Board. <br><b>Eisai<\/b> Other, Scientific Advisory Board. <br><b>Immunogen<\/b> Other, Scientific Advisory Board. <br><b>Ovarian Cancer Research Alliance<\/b> Other, Scientific Advisory Board. <br><b>Allarity<\/b> Other, Scientific Advisory Board. <br><b>Eli Lilly<\/b> Other, Scientific Advisory Board. <br><b>Alkermes<\/b> Other, member of Data safety monitoring committee. <br><b>Symphogen<\/b> Other, member of Data safety monitoring committee. <br><b>P. Konstantinopoulos, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Advisory board\/consulting. <br><b>Pfizer<\/b> Grant\/Contract, Other, Advisory board\/consulting. <br><b>Eli Lilly<\/b> Grant\/Contract. <br><b>Bayer<\/b> Grant\/Contract. <br><b>Merck<\/b> Grant\/Contract, Other, Advisory board\/consulting. <br><b>GSK<\/b> Grant\/Contract, Other, Advisory board\/consulting. <br><b>Merck KGaA<\/b> Grant\/Contract. <br><b>Immunogen<\/b> Other, Advisory board\/consulting. <br><b>Novartis<\/b> Other, Advisory board\/consulting. <br><b>Alkermes<\/b> Other, Advisory board\/consulting. <br><b>EMD Serono<\/b> Other, Advisory board\/consulting. <br><b>BMS<\/b> Other, Advisory board\/consulting. <br><b>Artios<\/b> Other, Advisory board\/consulting. <br><b>Schrodinger<\/b> Other, Advisory board\/consulting.","End":"4\/7\/2024 4:45:00 PM","HasWebcast":null,"Highlights":[],"Id":"11425","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT008","PresenterBiography":null,"PresenterDisplayName":"Rebecca Porter, MD;PhD","PresenterKey":"1955acba-a6fb-49c8-bf1f-3662c966a6e5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT008. A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:30PM","SessionId":"660","SessionOnDemand":"False","SessionTitle":"Novel Immune Checkpoint Inhibitor Combinations","ShowChatLink":"false","Start":"4\/7\/2024 4:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"f20ac754-3b9d-40d0-8d01-b097aec2d62c","ControlNumber":"12134","DisclosureBlock":"","End":"4\/7\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11833","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:30PM","SessionId":"660","SessionOnDemand":"False","SessionTitle":"Novel Immune Checkpoint Inhibitor Combinations","ShowChatLink":"false","Start":"4\/7\/2024 4:45:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT06-01 Phase III adult clinical trials,,"},{"Key":"Keywords","Value":"Cancer immunotherapy,Head and neck squamous cell carcinoma,Checkpoint Inhibitors,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. J. Wong<\/b><sup>1<\/sup>, J. Fayette<sup>2<\/sup>, M. Teixeira<sup>3<\/sup>, K. Prabhash<sup>4<\/sup>, R. Mesia<sup>5<\/sup>, A. Kawecki<sup>6<\/sup>, A. Dechaphunkul<sup>7<\/sup>, J. Dinis<sup>8<\/sup>, Y. Guo<sup>9<\/sup>, M. Masuda<sup>10<\/sup>, C.-Y. Hsieh<sup>11<\/sup>, M. Ghi<sup>12<\/sup>, C. Vaz de Melo Sette<sup>13<\/sup>, T. Jiang<sup>14<\/sup>, Y. Yan<sup>14<\/sup>, M. Kaul<sup>14<\/sup>, R. Jagtiani<sup>14<\/sup>, C. Matheny<sup>14<\/sup>, V. Cuchelkar<sup>14<\/sup>, R. Haddad<sup>15<\/sup>; <br\/><sup>1<\/sup>UCLA Medical Center, Los Angeles, CA, <sup>2<\/sup>Centre Leon Berard, Département d’Hématologie et d’Oncologie, Lyon, France, <sup>3<\/sup>IPO de Coimbra, Servico de Oncologia Medica, Coimbra, Portugal, <sup>4<\/sup>Tata Memorial Hospital, Department of Medical Oncology, Mumbai, India, <sup>5<\/sup>Catalan Institute of Oncology, Hospitalet de Llobregat, Spain, <sup>6<\/sup>Maria Sk&#322;odowska-Curie National Research Institute of Oncology, Warsaw, Poland, <sup>7<\/sup>Songklanagarind Hospital, Department of Oncology, Prince of Songkla University, Hat Yai District, Thailand, <sup>8<\/sup>IPO do Porto, Servico de Oncologia Medica, Porto, Portugal, <sup>9<\/sup>Shanghai East Hospital, Tongji University, Shanghai, China, <sup>10<\/sup>National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan, <sup>11<\/sup>Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, <sup>12<\/sup>IOV - Istituto Oncologico Veneto IRCCS, Pauda, Italy, <sup>13<\/sup>Faculdade de Medicina do ABC – FMABC, Santo André, Brazil, <sup>14<\/sup>Genentech, Inc., South San Francisco, CA, <sup>15<\/sup>Dana-Farber Cancer Institute, Boston, MA","CSlideId":"","ControlKey":"3eee549b-ddd1-4b64-aa44-3b370a33e7fa","ControlNumber":"9683","DisclosureBlock":"<b>&nbsp;D. J. Wong, <\/b> <br><b>Regeneron, Merck<\/b> Other, Consulting or advisory role. <br><b>Lilly<\/b> Research funding. <br><b>Merck Serono, Merck Sharp & Dohme, ARMO BioSciences, AstraZeneca\/MedImmune, Kura, Regeneron, Genentech\/Roche, Bristol-Myers Squibb, FSTAR, Pfizer, Astellas, Enzychem Lifesciences, Elevar Therapeutics<\/b> Research funding to the institution. <br><b>TopAlliance BioSciences Inc, Checkmate Pharmaceuticals, Bicara Therapeutics, Gilead Sciences, Flamingo Pharma, Hookipa Biotech, Lilly<\/b> Research funding to the institution. <br><b>J. Fayette, <\/b> <br><b>MSD, Merck, Sanofi, BMS, F. Hoffmann-La Roche Ltd, AstraZeneca<\/b> Other, Honoraria. <br><b>Merck, Seagen, Hookipa, Elevar<\/b> Other, Consulting or advisory role. <br><b>MSD, Merck<\/b> Travel.<br><b>M. Teixeira, <\/b> None.&nbsp;<br><b>K. Prabhash, <\/b> <br><b>Zydua Pharma, Pfizer Gulf FZ=LLC<\/b> Other, Honoraria (for the institution). <br><b>Aurigene Discovery, Janssen & Janssen, Roche Ind Pvt Ltd, Cadilla Pvt Ltd<\/b> Other, Research funding (for the institution). <br><b>R. Mesia, <\/b> <br><b>Merck, Nanobiotix, MSD, BMS, F. Hoffmann-La Roche Ltd, Seagen, AstraZeneca, Pfizer, Boehringer, GSK<\/b> Other, Consulting or advisory role. <br><b>Merck, MSD, Boehringer<\/b> Other, Speaker’s Bureau. <br><b>MSD, Merck<\/b> Travel. <br><b>A. Kawecki, <\/b> <br><b>MSC National Research Institute of Oncology<\/b> Employment. <br><b>MSD, BMS, Merck, AstraZeneca, F. Hoffmann-La Roche Ltd, Sanofi, GSK<\/b> Other, Honoraria. <br><b>MSD, Merck, BMS<\/b> Other, Consulting or advisory role. <br><b>A. Dechaphunkul, <\/b> <br><b>BeiGene<\/b> Other, Consulting or advisory role. <br><b>J. Dinis, <\/b> <br><b>IPO Porto<\/b> Employment. <br><b>PharmaMar, Gilead<\/b> Travel. <br><b>Y. Guo, <\/b> <br><b>Merck Serono, MSD, F. Hoffmann-La Roche Ltd, BeiGene<\/b> Other, Honoraria. <br><b>Merck Serono, MSD, F. Hoffmann-La Roche Ltd, GSK<\/b> Other, Consulting or advisory role. <br><b>M. Masuda, <\/b> <br><b>Abbott Japan<\/b> Other, Consulting or advisory role. <br><b>Abbott Japan<\/b> Other, Speaker’s Bureau.<br><b>C. Hsieh, <\/b> None.&nbsp;<br><b>M. Ghi, <\/b> <br><b>MSD, BMS, Merck Serono<\/b> Other, Consulting or advisory role. <br><b>C. Vaz de Melo Sette, <\/b> <br><b>CEPHO<\/b> Employment. <br><b>Janssen, AstraZeneca<\/b> Other, Consulting or advisory role. <br><b>Janssen, AstraZeneca, Pfizer, Sanofi<\/b> Other, Speaker’s Bureau. <br><b>T. Jiang, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>F. Hoffmann-La Roche Ltd<\/b> Stock. <br><b>Y. Yan, <\/b> <br><b>Genentech, Inc.\/F. Hoffmann-La Roche Ltd<\/b> Employment. <br><b>F. Hoffmann-La Roche Ltd<\/b> Stock. <br><b>M. Kaul, <\/b> <br><b>Genentech, Inc.\/F. Hoffmann-La Roche Ltd<\/b> Employment. <br><b>F. Hoffmann-La Roche Ltd<\/b> Stock. <br><b>R. Jagtiani, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>C. Matheny, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>V. Cuchelkar, <\/b> <br><b>F. Hoffmann-La Roche Ltd<\/b> Employment, Stock. <br><b>R. Haddad, <\/b> <br><b>Dana-Farber Cancer Institute<\/b> Employment. <br><b>NCCN<\/b> Other, Leadership. <br><b>TOSK<\/b> Stock. <br><b>Merck, Eisai, BMS, AstraZeneca, GSK, EMD, Serono, Bayer, Coherus Biosciences, Boehringer Ingelheim<\/b> Other, Consulting or advisory role. <br><b>Merck, BMS, AstraZeneca, Genentech, Inc., Pfizer, Kura, EMD Serono, Incyte<\/b> Other, Research funding. <br><b>Nanobiotix, ISA Pharmaceuticals, Boehringer Ingelheim, Hookipa Pharma<\/b> Other, Data and Safety Monitoring Board relationships.","End":"4\/7\/2024 5:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"11426","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT009","PresenterBiography":null,"PresenterDisplayName":"Deborah Wong, MD;PhD","PresenterKey":"625bace9-8266-47d9-b0a0-41d8b0db4e28","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT009. IMvoke010: A<b> <\/b>phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:30PM","SessionId":"660","SessionOnDemand":"False","SessionTitle":"Novel Immune Checkpoint Inhibitor Combinations","ShowChatLink":"false","Start":"4\/7\/2024 5:00:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"IMvoke010: A<b> <\/b>phase III, double-blind randomized trial of atezolizumab (atezo) after definitive local therapy vs placebo in patients (pts) with high-risk locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN)","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Other","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":". ","CSlideId":"","ControlKey":"2bd4ae41-79d7-4144-8f01-3bba92d7ad1e","ControlNumber":"12135","DisclosureBlock":"","End":"4\/7\/2024 5:30:00 PM","HasWebcast":null,"Highlights":[],"Id":"11834","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":null,"PresenterKey":null,"PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Discussion","SearchResultFooter":"","SearchResultHeader":"Apr  7 2024  3:30PM","SessionId":"660","SessionOnDemand":"False","SessionTitle":"Novel Immune Checkpoint Inhibitor Combinations","ShowChatLink":"false","Start":"4\/7\/2024 5:15:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Discussion","Topics":null,"cSlideId":""}]